STOCK TITAN

Bristol-Myers Squibb (BMY) Insider Files Form 144 for 56,000 Shares

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Bristol-Myers Squibb Co. (BMY) filed a Form 144 notifying the proposed sale of 56,000 shares of common stock through Fidelity Brokerage Services LLC on the NYSE with an aggregate market value of $2,648,800.00. The filing reports total shares outstanding of 2,035,435,838 and an approximate sale date of 09/02/2025. The shares to be sold were acquired over 2021–2023 through stock option exercises and restricted stock vesting, with acquisition amounts listed by date (e.g., 2,976 on 08/12/2021; 19,326 on 09/13/2022). No securities were reported sold in the past three months.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine Form 144 disclosing an insider sale of 56,000 shares (approximate value $2.65M) sourced from prior compensation and option exercises.

The filing documents a proposed sale through Fidelity on the NYSE with explicit acquisition history showing stock option exercises and restricted stock vesting across 2021–2023. The size of the sale relative to total outstanding shares (2,035,435,838) is small. There are no reported sales in the prior three months, and the filer affirms no undisclosed material adverse information. Impact appears procedural rather than company-changing.

TL;DR: Disclosure meets Rule 144 requirements and identifies compensation-related share sources, indicating compliance-focused reporting.

The schedule breaks down the origin of shares (option exercises and vesting) with dates and amounts, which supports transparency about the insider's basis and timing. The filing includes the standard representation regarding material nonpublic information and does not indicate reliance on a 10b5-1 plan in the remarks. This is a routine insider sale notice with limited material impact on governance or capitalization.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What shares does the BMY Form 144 propose to sell?

The notice proposes sale of 56,000 shares of common stock.

Through which broker will the BMY shares be sold?

The filing lists Fidelity Brokerage Services LLC (900 Salem Street, Smithfield RI) as the broker.

What is the aggregate market value and planned sale date in the BMY Form 144?

Aggregate market value is $2,648,800.00 with an approximate sale date of 09/02/2025.

How many BMY shares are outstanding according to the filing?

The filing reports 2,035,435,838 shares outstanding.

What were the sources of the shares listed in the Form 144?

Shares were acquired via stock option exercises and restricted stock vesting between 08/12/2021 and 03/10/2023, with specific amounts listed per date.

Did the filer report any sales in the past three months?

The filing states Nothing to Report for securities sold during the past three months.
Bristol-Myers Squibb Co

NYSE:BMY

BMY Rankings

BMY Latest News

BMY Latest SEC Filings

BMY Stock Data

111.38B
2.03B
0.07%
82.82%
1.53%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States
PRINCETON